文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Personalized medicine in colorectal cancer.

作者信息

Vaseghi Maghvan Padina, Jeibouei Shabnam, Akbari Mohammad Esmael, Niazi Vahid, Karami Farshid, Rezvani Alireza, Ansarinejad Nafiseh, Abbasinia Masroor, Sarvari Gisoo, Zali Hakimeh, Talaie Ramin

机构信息

Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

Gastroenterol Hepatol Bed Bench. 2020 Winter;13(Suppl1):S18-S28.


DOI:
PMID:33585000
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7881405/
Abstract

Colorectal cancer (CRC) is a heterogeneous disease with various genetic and epigenetic factors leading to difficulties in response to both the therapy and drug resistance. Moreover, even in tumors with similar histopathological characteristics, different responses and molecular features could be observed because of the genetic basis and its interactions with the living environment. Through personalized medicine, we can classify patients into separate groups according to their genetic and epigenetic features and their susceptibility for a specific disease which could help with choosing the best therapeutic approach. In this review, genetic and epigenetic factors that cause heterogeneity in colorectal cancer are evaluated and proper drug administration in both chemotherapy and target therapy are suggested.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18b/7881405/d8db8c508202/GHFBB-13-S18-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18b/7881405/280462e2c31c/GHFBB-13-S18-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18b/7881405/8a4176dbd09a/GHFBB-13-S18-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18b/7881405/d8db8c508202/GHFBB-13-S18-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18b/7881405/280462e2c31c/GHFBB-13-S18-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18b/7881405/8a4176dbd09a/GHFBB-13-S18-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f18b/7881405/d8db8c508202/GHFBB-13-S18-g003.jpg

相似文献

[1]
Personalized medicine in colorectal cancer.

Gastroenterol Hepatol Bed Bench. 2020

[2]
Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.

Curr Drug Targets. 2018

[3]
Early-onset colorectal cancer: a separate subset of colorectal cancer.

World J Gastroenterol. 2014-12-14

[4]
The heterogeneous clinical and pathological landscapes of metastatic -mutated colorectal cancer.

Cancer Cell Int. 2020-1-29

[5]
Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer.

Int J Environ Res Public Health. 2016-9-8

[6]
Current and future biomarkers in the treatment of colorectal cancer.

Acta Clin Belg. 2017-4

[7]
From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy.

Clin Colorectal Cancer. 2016-6

[8]
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.

Drug Resist Updat. 2011-9-28

[9]
Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.

Semin Cell Dev Biol. 2016-8-27

[10]
[Looking back 2018--focused on colorectal cancer].

Zhonghua Wei Chang Wai Ke Za Zhi. 2019-1-25

引用本文的文献

[1]
Overall survival post secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal cancer with peritoneal metastases.

World J Surg Oncol. 2025-7-23

[2]
KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients.

Curr Issues Mol Biol. 2025-2-12

[3]
Evaluation of the influence of trastuzumab therapy on serum levels of HER-2 protein and breast cancer cell lines.

Prz Menopauzalny. 2024-6

[4]
Colorectal cancer: Recent advances in management and treatment.

World J Clin Oncol. 2024-9-24

[5]
Unlocking the Potential of RNA Nanoparticles: A Breakthrough Approach to Overcoming Challenges in Colon Cancer Treatment.

Curr Pharm Biotechnol. 2025

[6]
CEA-delta could be a biomarker of tumor phenotype, clinical stage, and chemotherapeutic response in rectal cancer with OCT4-positive cancer stem cells.

Front Oncol. 2023-9-7

[7]
Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors.

Front Med (Lausanne). 2023-5-4

[8]
Asparagine and Glutamine Deprivation Alters Ionizing Radiation Response, Migration and Adhesion of a p53 Colorectal Cancer Cell Line.

Int J Mol Sci. 2023-2-3

[9]
Secretin Receptor as a Target in Gastrointestinal Cancer: Expression Analysis and Ligand Development.

Biomedicines. 2022-2-24

本文引用的文献

[1]
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.

Clin Colorectal Cancer. 2019-7-15

[2]
Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting.

Transl Oncol. 2019-3

[3]
Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.

J Cell Physiol. 2018-11-27

[4]
Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review).

Oncol Rep. 2018-3-21

[5]
and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

Oncotarget. 2017-12-21

[6]
Therapeutic potential and critical analysis of trastuzumab and bevacizumab in combination with different chemotherapeutic agents against metastatic breast/colorectal cancer affecting various endpoints.

Crit Rev Oncol Hematol. 2016-6-16

[7]
Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.

Dig Dis. 2016

[8]
Insights into next developments in advanced gastric cancer.

Curr Opin Oncol. 2016-7

[9]
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.

J Pathol. 2016-3

[10]
Regorafenib in the treatment of colorectal cancer.

Expert Opin Pharmacother. 2016

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索